公开(公告)号：US09238639B2

公开(公告)日：2016-01-19

申请号：US14380215

申请日：2013-02-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Nobuyuki Takakura ,  Yoshihiro Banno ,  Yoshito Terao ,  Atsuko Ochida ,  Sachie Morimoto ,  Tsuneo Yasuma ,  Minoru Ikoma ,  Kei Masuda

IPC: C07D333/60 ,  C07D417/12 ,  C07D495/04 ,  C07D333/54 ,  C07D405/04 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D307/79 ,  C07D307/80 ,  C07D307/81 ,  C07D307/84 ,  C07D333/64 ,  C07D333/70

CPC classification number: C07D333/60 ,  C07D307/79 ,  C07D307/80 ,  C07D307/81 ,  C07D307/84 ,  C07D333/54 ,  C07D333/64 ,  C07D333/70 ,  C07D405/04 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D417/12 ,  C07D495/04

Abstract: The present invention provides a compound having a GOAT inhibitory action, which is useful for the prophylaxis or treatment of obesity and the like, and has superior efficacy. The present invention is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有GOAT抑制作用的化合物，其可用于预防或治疗肥胖症等，并且具有优异的疗效。 本发明是由式（I）表示的化合物：其中各符号如说明书中所定义，或其盐。

公开(公告)号：US20150018547A1

公开(公告)日：2015-01-15

申请号：US14380215

申请日：2013-02-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Nobuyuki Takakura ,  Yoshihiro Banno ,  Yoshito Terao ,  Atsuko Ochida ,  Sachie Morimoto ,  Shuji Kitamura ,  Yoshihide Tomata ,  Tsuneo Yasuma ,  Minoru Ikoma ,  Kei Masuda

IPC: C07D333/60 ,  C07D307/80 ,  C07D495/04 ,  C07D417/12 ,  C07D333/70 ,  C07D333/64 ,  C07D409/12 ,  C07D405/12

CPC classification number: C07D333/60 ,  C07D307/79 ,  C07D307/80 ,  C07D307/81 ,  C07D307/84 ,  C07D333/54 ,  C07D333/64 ,  C07D333/70 ,  C07D405/04 ,  C07D405/12 ,  C07D409/06 ,  C07D409/12 ,  C07D417/12 ,  C07D495/04

Abstract: The present invention provides a compound having a GOAT inhibitory action, which is useful for the prophylaxis or treatment of obesity and the like, and has superior efficacy. The present invention is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有GOAT抑制作用的化合物，其可用于预防或治疗肥胖症等，并且具有优异的疗效。 本发明是由式（I）表示的化合物：其中各符号如说明书中所定义，或其盐。

公开(公告)号：US12091410B2

公开(公告)日：2024-09-17

申请号：US17413473

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Norihito Tokunaga ,  Tsuneo Oda ,  Tohru Miyazaki ,  Dilhumar Uyghur ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Keisuke Imamura ,  Takahiro Sugimoto ,  Koichiro Fukuda ,  Yasuhisa Kohara ,  Rei Okamoto ,  Taiichi Ohra ,  Naoki Miyamoto ,  Yoshito Terao ,  Masanori Kawasaki

IPC: C07D471/04 ,  C07D215/38 ,  C07D231/56 ,  C07D277/64 ,  C07D401/14

CPC classification number: C07D471/04 ,  C07D215/38 ,  C07D231/56 ,  C07D277/64 ,  C07D401/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US12071434B2

公开(公告)日：2024-08-27

申请号：US17413469

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuhei Miyanohana ,  Yuichi Kajita ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Norihito Tokunaga ,  Tsuneo Oda ,  Tohru Miyazaki ,  Dilhumar Uyghur ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Keisuke Imamura ,  Takahiro Sugimoto ,  Koichiro Fukuda ,  Yasuhisa Kohara ,  Rei Okamoto ,  Taiichi Ohra ,  Naoki Miyamoto ,  Jun Chiba ,  Yoshito Terao ,  Masanori Kawasaki

IPC: C07D455/02 ,  A61P25/26 ,  C07D217/24 ,  C07D237/32 ,  C07D239/90 ,  C07D401/06 ,  C07D401/10 ,  C07D403/10 ,  C07D417/06 ,  C07D471/04 ,  C07D498/04

CPC classification number: C07D455/02 ,  A61P25/26 ,  C07D217/24 ,  C07D237/32 ,  C07D239/90 ,  C07D401/06 ,  C07D401/10 ,  C07D403/10 ,  C07D417/06 ,  C07D471/04 ,  C07D498/04 ,  C07B2200/05

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10968178B2

公开(公告)日：2021-04-06

申请号：US16496530

申请日：2018-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshito Terao ,  Masashi Takahashi ,  Ryoma Hara ,  Kousuke Hidaka ,  Hideki Furukawa ,  Takeshi Yamasaki ,  Shizuo Kasai

IPC: C07D209/96 ,  C07D401/12 ,  C07D403/12 ,  C07D471/10 ,  C07D491/052 ,  A61P3/10 ,  A61P9/04

Abstract: The present invention aims to provide a heterocyclic compound having an IP6K inhibitory action and expected to be useful as a prophylactic or therapeutic agent for—diseases such as cardiac failure, diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the SPECIFICATION, or a salt thereof has an IP6K inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for diseases such as cardiac failure, diabetes and the like.

公开(公告)号：US08921358B2

公开(公告)日：2014-12-30

申请号：US13852924

申请日：2013-03-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Edcon Chang ,  Matthew H. McNeill ,  Tracy Duong ,  Angie Vassar ,  Takehiro Hirano ,  Yoshito Terao

IPC: A61K31/519 ,  C07D487/04

CPC classification number: C07D487/04 ,  A61K31/519

Abstract: The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formula wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Abstract translation: 本发明涉及抑制下式化合物的凋亡信号调节激酶1（“ASK1”），其中变量如本文所定义。 本发明还涉及包含这些化合物的药物组合物，试剂盒和制品; 用于制备化合物的方法和中间体; 以及使用所述化合物的方法。